is retatrutide legal ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Retatrutide Promises Big Weight Loss,

Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction

On social media, most of the microdosing chatter is about small amounts of weight loss, perceived (but not proven!) longevity benefits, and treating many forms of inflammation

Overall prescribing trends The study found that 2,185,238 patients were prescribed a GLP-1 RA between January 2019 and December 2025, with 11,194,909 total prescriptions during this period

Ethics declarations Conflict of Interest The authors declare the following conflicts of interest: Carlos E

They work in complex ways that were still learning about

key role of GLP-1R